Nekoua Magloire Pandoua, Dechaumes Arthur, Sane Famara, Alidjinou Enagnon Kazali, Moutairou Kabirou, Yessoufou Akadiri, Hober Didier
Laboratoire de Virologie ULR3610, Univ Lille, CHU Lille, F-59000 Lille, France.
Laboratoire de Biologie et Physiologie Cellulaire, Institut des Sciences Biomédicales Appliquées (ISBA), Faculté des Sciences et Techniques (FAST), Université d'Abomey-Calavi, Cotonou 01 BP 526, Benin.
Microorganisms. 2020 Jul 1;8(7):989. doi: 10.3390/microorganisms8070989.
Enteroviruses, especially group B coxsackieviruses (CV-B), have been associated with the development of chronic diseases such as type 1 diabetes (T1D). The pathological mechanisms that trigger virus-induced autoimmunity against islet antigens in T1D are not fully elucidated. Animal and human studies suggest that NK cells response to CV-B infection play a crucial role in the enteroviral pathogenesis of T1D. Indeed, CV-B-infected cells can escape from cytotoxic T cells recognition and destruction by inhibition of cell surface expression of HLA class I antigen through non-structural viral proteins, but they can nevertheless be killed by NK cells. Cytolytic activity of NK cells towards pancreatic beta cells persistently-infected with CV-B has been reported and defective viral clearance by NK cells of patients with T1D has been suggested as a mechanism leading to persistence of CV-B and triggering autoimmunity reported in these patients. The knowledge about host antiviral defense against CV-B infection is not only crucial to understand the susceptibility to virus-induced T1D but could also contribute to the design of new preventive or therapeutic approaches for individuals at risk for T1D or newly diagnosed patients.
肠道病毒,尤其是B组柯萨奇病毒(CV-B),与1型糖尿病(T1D)等慢性疾病的发生有关。引发T1D中针对胰岛抗原的病毒诱导自身免疫的病理机制尚未完全阐明。动物和人体研究表明,NK细胞对CV-B感染的反应在T1D的肠道病毒发病机制中起关键作用。确实,感染CV-B的细胞可通过病毒非结构蛋白抑制HLA I类抗原的细胞表面表达,从而逃避细胞毒性T细胞的识别和破坏,但它们仍可被NK细胞杀死。已有报道称NK细胞对持续感染CV-B的胰腺β细胞具有细胞溶解活性,并且有人提出T1D患者的NK细胞病毒清除缺陷是导致这些患者中CV-B持续存在并引发自身免疫的一种机制。了解宿主针对CV-B感染的抗病毒防御不仅对于理解病毒诱导的T1D易感性至关重要,而且还可能有助于为有T1D风险的个体或新诊断患者设计新的预防或治疗方法。